| IQV |
Report |
Q2 revenue |
BEAT |
pred ~$4.35B vs. cons $4.30B |
MEDIUM |
| IQV |
Report |
Q2 adjusted EBITDA |
BEAT |
pred ~$981M vs. cons $966M |
MEDIUM |
| IQV |
Report |
Q2 adjusted diluted EPS |
BEAT |
pred ~$3.10 vs. cons $3.03 |
HIGH |
| IQV |
Guide |
Revenue guidance |
BETTER |
guide ~$17.35B vs. cons $17.30B (FY2026) |
MEDIUM |
| IQV |
Guide |
Adjusted EBITDA guidance |
BETTER |
guide ~$4.03B vs. cons $4.00B (FY2026) |
MEDIUM |
| IQV |
Guide |
Adjusted diluted EPS guidance |
BETTER |
guide ~$13.00 vs. cons $12.85 (FY2026) |
MEDIUM |
| IQV |
Return |
Day-1 residual (stock − beta × S&P 500) |
+4.2% |
— |
MEDIUM |
| IQV |
Return |
5-day cumulative residual |
+5.3% (FOLLOW-THROUGH) |
FY revenue guide of ~$17.35B less predicted H1 revenue of ~$8.50B implies H2 revenue of ~$8.85B, above the prior midpoint-implied ~$8.79B; the absence of an implicit out-period cut should support positive estimate revisions after the initial beat. |
MEDIUM |